Viral Mutation Section, HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702-1201, USA.
J Virol. 2010 Dec;84(24):12599-608. doi: 10.1128/JVI.01437-10. Epub 2010 Oct 13.
Human APOBEC3F (hA3F) and human APOBEC3G (hA3G) are potent anti-human immunodeficiency virus (anti-HIV) host factors that suppress viral replication by hypermutating the viral genome, inhibiting reverse transcription, and hindering integration. To overcome hA3F and hA3G, HIV-1 encodes Vif, which binds and targets these host proteins for proteasomal degradation. Previously, we reported that the hA3F-Vif interactions that lead to hA3F degradation are located in the region comprising amino acids 283 to 300. We have now performed mutational analysis of this region and found that the (289)EFLARH(294) amino acids contribute to hA3F-Vif binding and are critical for A3F's sensitivity to Vif. Mutants in which E289 is mutated significantly increase hA3F's ability to inhibit viral infectivity in the presence of Vif, and coimmunoprecipitation assays show that binding of Vif to the E289K mutant is decreased. We examined the role of the EFLARH sequence in other A3 proteins, including human A3C (hA3C), human A3DE (hA3DE), African green monkey A3F (agmA3F), and rhesus macaque A3F (rhA3F). hA3C, hA3DE, and agmA3F were all susceptible to degradation induced by HIV-1 Vif, while rhA3F was not. Mutagenesis of the glutamate in the EFLARH sites of hA3C, hA3DE, and agmA3F decreases the susceptibilities of these proteins to Vif-induced degradation. Together, these results indicate that the EFLARH region in hA3F, hA3C, hA3DE, and agmA3F interacts with HIV-1 Vif and that this interaction plays a role in the Vif-mediated proteasomal degradation of these A3 proteins. These studies identify a conserved region in 3 of 7 human A3 proteins that is critical for degradation mediated by HIV-1 Vif and provide structural insights into the hA3F-Vif interactions that could facilitate the development of a novel class of anti-HIV agents.
人 APOBEC3F(hA3F)和人 APOBEC3G(hA3G)是强有力的抗人类免疫缺陷病毒(抗 HIV)宿主因子,通过使病毒基因组发生超突变、抑制逆转录和阻碍整合来抑制病毒复制。为了克服 hA3F 和 hA3G,HIV-1 编码了 Vif,它与这些宿主蛋白结合并将其靶向蛋白酶体降解。此前,我们报道了导致 hA3F 降解的 hA3F-Vif 相互作用位于包含氨基酸 283 至 300 的区域。我们现在已经对该区域进行了突变分析,发现(289)EFLARH(294)氨基酸有助于 hA3F-Vif 结合,并且对 A3F 对 Vif 的敏感性至关重要。其中 E289 发生突变的突变体显著增加了 hA3F 在存在 Vif 的情况下抑制病毒感染性的能力,共免疫沉淀测定表明 Vif 与 E289K 突变体的结合减少。我们研究了 EFLARH 序列在其他 A3 蛋白(包括人 A3C(hA3C)、人 A3DE(hA3DE)、非洲绿猴 A3F(agmA3F)和恒河猴 A3F(rhA3F))中的作用。hA3C、hA3DE 和 agmA3F 均易受 HIV-1 Vif 诱导的降解,而 rhA3F 则不易受影响。EFLARH 位点谷氨酸的突变降低了这些蛋白对 Vif 诱导降解的易感性。总之,这些结果表明 hA3F、hA3C、hA3DE 和 agmA3F 中的 EFLARH 区域与 HIV-1 Vif 相互作用,并且这种相互作用在 Vif 介导的这些 A3 蛋白的蛋白酶体降解中发挥作用。这些研究鉴定出 7 个人 A3 蛋白中的 3 个保守区域对于 HIV-1 Vif 介导的降解至关重要,并为 hA3F-Vif 相互作用提供了结构见解,这可能有助于开发一类新型抗 HIV 药物。